WG

GeneDx Holdings Corp

WGS
Accountable AI Logo

GeneDx Holdings Corp AI Insights

Informational only. Not investment advice.
As of 2025-12-10

Snapshot

  • Revenue grew 52% TTM vs industry median 9% - 5.5x faster growth with gross margin of 70% (vs 44% median)[Total Revenue 1Y Growth]
  • Intangibles are 63% of assets (185M) vs tangible book of 107M - acquisition-heavy model with impairment risk[Goodwill and Other Intangible Assets]
  • P/E of 672x and P/S of 11.4x (vs median 1.5x) prices in years of flawless execution[P/E Ratio]

Watch Triggers

  • Gross Margin TTM: Falls below 65%Unit economics thesis breaks if pricing power erodes or test costs rise
  • Total Revenue 1Y Growth: Decelerates below 30%Valuation requires hypergrowth - deceleration triggers multiple compression
  • Operating Margin TTM: Turns negativeJust achieved profitability - reversal signals operating leverage thesis failed

Bull Case

Gross profit growth of 77% TTM outpacing revenue 52% shows unit economics improving - path to profitability accelerating

Gross Profit 1Y GrowthGross Margin TTM

Working capital of 150M (37% of revenue) with 96M cash provides runway without dilution at current burn rate

Working CapitalCash and Equivalents

Bear Case

P/E of 672x requires 20x earnings growth to reach industry median 35x - any execution miss devastates valuation

P/E RatioP/S Ratio

Net margin of 0.5% TTM means profitability is fragile - one bad quarter returns to losses

Net Margin TTMNet Income TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
35%

Leverage WGS's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Operating leverage should drive margin expansion as R&D (15% of revenue) scales with volume

1-3ymed
  • Gross margin 70% provides headroom
  • Operating margin just turned positive at 2.5%
  • R&D of 59M can spread across growing revenue base
Gross profit grew 77% vs revenue 52% TTMEBITDA of 34M up from likely negative prior yearOperating expense flat relative to revenue growth
Valuation Context
Caveats

Public Strategies Rankings

See how GeneDx Holdings Corp ranks across different investment strategies.

Leverage WGS's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2025 Accountable Finance, Inc. All rights reserved.